BioNexus Gene Lab Corp. Diluted Shares Outstanding (Weighted Average)
BioNexus Gene Lab Corp. (BGLC) reported Diluted Shares Outstanding (Weighted Average) of 2.42 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-14
- BioNexus Gene Lab Corp. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 2.42M shares, a 34.55% increase year-over-year.
- BioNexus Gene Lab Corp. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 2.42M shares, a 34.54% increase year-over-year.
- BioNexus Gene Lab Corp. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 1.80M shares, a 0.01% decline year-over-year.
- BioNexus Gene Lab Corp. weighted average number of shares outstanding, diluted for the quarter ending 2025-06-30 was 1.80M shares, a 1.69% increase year-over-year.
- BioNexus Gene Lab Corp. weighted average number of shares outstanding, diluted for fiscal 2024 was 17.82M shares, a 12.24% increase from fiscal 2023.
- BioNexus Gene Lab Corp. weighted average number of shares outstanding, diluted for fiscal 2023 was 15.88M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 2.42M shares 10-Q · filed 2026-08-14 | 2.42M shares 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 2.42M shares 10-Q · filed 2026-05-15 | ||||
| 2025-09-30 | 1.80M shares 10-Q · filed 2025-11-14 | 1.80M shares derived: average of 2 quarters · filed 2026-08-14 | 1.80M shares 10-Q · filed 2025-11-14 | 17.83M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | 1.80M shares 10-Q · filed 2026-08-14 | 1.80M shares 10-Q · filed 2026-08-14 | 23.18M shares derived: average of 3 quarters · filed 2026-08-14 | 17.83M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | 1.80M shares 10-Q · filed 2026-05-15 | 17.97M shares 10-Q · filed 2025-05-15 | 33.87M shares derived: average of 2 quarters · filed 2026-05-15 | 23.18M shares derived: average of 3 quarters · filed 2026-05-15 | 17.83M shares derived: average of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | 65.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | 33.87M shares derived: average of 2 quarters · filed 2025-11-14 | 23.17M shares derived: average of 3 quarters · filed 2025-11-14 | 17.82M shares 10-K · filed 2025-04-15 | |
| 2024-09-30 | 1.80M shares 10-Q · filed 2025-11-14 | 1.78M shares derived: average of 2 quarters · filed 2025-11-14 | 1.78M shares 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | 1.77M shares 10-Q · filed 2025-08-18 | 1.77M shares 10-Q · filed 2025-08-18 | |||
| 2024-03-31 | 17.67M shares 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | 15.88M shares 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |